-
Sources of funding for pharmaceutical research has come under scrutiny in the last decade as academic and government sources of funding have become increasingly scarce and the pharmaceutical industry has become the main source of research dollars. But the issue of objectivity has been raised, and some have even suggested that negative studies, that is studies that show a drug in an unfavorable light, may never be published.
-
-
Sasser H. Faltering promise: Vitamin E and heart disease. Altern Med Alert 2004;7(9):101-104.
-
A new portrait of CAM use in the United States. Altern Med Alert 2004;7(9):S1-S2.
-
-
The 10-year disease-free and overall survival rate is presented from a trial of adjuvant therapy (chemo-, or immunotherapy) for Dukes B and C colon cancer conducted by the National Surgical Adjuvant Breast and Bowel cooperative group. The disease-free and overall survival advantage for the chemotherapy arm, apparent at 5 years, was no longer evident by 10 years.
-
Epirubicin and paclitaxel were administered either in combination or sequentially to 202 patients with metastatic breast cancer to demonstrate noninferiority of the sequential approach. Response rates and survival were comparable in the 2 groups, but toxicity was greater (neutropenia and neuropathy) in those that received the drugs sequentially rather than in combination.
-
Symptoms that are more severe or frequent than expected and of recent onset warrant further diagnostic investigation because they are more likely to be associated with both benign and malignant ovarian masses.
-
-
Annual, or less frequent, surveillance intervals are effective for aneurysms < 45 mm in diameter.
